Charles River Acquires Northwest Kinetics

Charles River Laboratories is pleased to announce that it has acquired Northwest Kinetics. Based in Tacoma, Washington, Northwest Kinetics is a 150-bed, early phase clinical pharmacology unit with expertise in branded drug studies. By acquiring Northwest Kinetics, Charles River establishes a Phase I Clinical Services capacity in North America, which in conjunction with its Phase I facility in Edinburgh, Scotland, positions it exceptionally well to support its clients' high-end clinical pharmacology studies. Between the two state-of-the-art facilities, Charles River will have over 200 beds, with an additional 100 beds currently being added to the Tacoma facility.

James C. Foster, Chairman, President, and Chief Executive Officer said, "Our mission is to support our clients' drug development needs from discovery to preclinical development to Phase I clinical trials, and the acquisition of Northwest Kinetics meets a key objective in strengthening our Phase I service offerings. With this acquisition, we can now offer high-end clinical pharmacology services in North America, complementing our presence in Scotland. Through its management's deep scientific and medical backgrounds, Northwest Kinetics has established itself as a premier provider of branded drug studies, and we expect to leverage that expertise on a global basis as we expand our Phase I service offerings. Northwest Kinetics' scientific excellence and outstanding customer service make it a superb fit for us, as these are the hallmarks of Charles River. We are very pleased to welcome Northwest Kinetics to the Charles River family."

SOURCE: Charles River Laboratories